Indian pharma stocks fell up to 3% after U.S. President Trump announced a 25% tariff on Indian imports over its trade with Russia. Concerns rose about potential inclusion of generic drugs in the tariff list. Analysts expect strategic shifts by exporters and a cautious, range-bound market reaction.
Sebi relaxes re-KYC process for NRIs; removes physical presence clause
Markets regulator Sebi on Wednesday eased the re-KYC process for Non-Resident Indians (NRIs) by removing the requirement for them to be physically present in India